{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:59:16Z","timestamp":1781049556050,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) reactivation consequent to immunosuppressive therapy is an increasingly prevalent problem with serious clinical implications. Treatment with biologic agents conduces to the loss of protective antibody to HBV surface antigen (anti-HBs), which significantly increases the risk of HBV reactivation. Hence, we investigated the risk factors for losing anti-HBs in patients with rheumatic diseases and HBV surface antigen negative\/anti-HBs positive (HBsAg\u2212\/anti-HBs+) serostatus during treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a nested case-control design, we prospectively enrolled patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis\/psoriasis, or juvenile idiopathic arthritis, who were treated with biologic DMARDs at Changhua Christian Hospital, Taiwan, from January 2013 to June 2019 and had HBsAg\u2212\/anti-HBs+\u2009serostatus; the analytic sample excluded all patients with HBsAg+ or anti-HBs\u2212\u2009serostatus. Anti-HBs titers were monitored 6-monthly and cases were defined as anti-HBs &lt;\u200910 mIU\/ml during follow-up. Cases were matched one-to-all with controls with anti-HBs \u2265\u00a010 mIU\/ml on the same ascertainment date and equivalent durations of biologic DMARDs treatment (control patients could be resampled and could also become cases during follow-up). Between-group characteristics were compared and risk factors for anti-HBs loss were investigated by conditional logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 294 eligible patients, 23 cases were matched with 311 controls. The incidence of anti-HBs loss was ~\u20092.7%\/person-year during biologic DMARDs treatment. Besides lower baseline anti-HBs titer (risk ratio 0.93, 95% CI 0.89\u20130.97), cases were significantly more likely than controls to have diabetes mellitus (risk ratio 4.76, 95% CI 1.48\u201315.30) and chronic kidney disease (risk ratio 14.00, 95% CI 2.22\u201388.23) in univariate analysis. Risk factors remaining significantly associated with anti-HBs loss in multivariate analysis were lower baseline anti-HBs titer (adjusted risk ratio 0.93, 95% CI 0.88\u20130.97) and chronic kidney disease (adjusted risk ratio 45.68, 95% CI 2.39\u2013871.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Besides lower baseline anti-HBs titer, chronic kidney disease also strongly predicts future anti-HBs negativity in patients with HBsAg\u2212\/anti-HBs+\u2009serostatus who receive biologic DMARDs to treat rheumatic diseases. Patients with low anti-HBs titer (\u2264 100 mIU\/ml) and\/or chronic kidney disease should be monitored during biologic DMARDs therapy, to enable timely prophylaxis to preempt potential HBV reactivation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-021-00173-9","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T09:03:17Z","timestamp":1617872597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative\/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study"],"prefix":"10.1186","volume":"61","author":[{"given":"Ming-Hui","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chih","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-5331","authenticated-orcid":false,"given":"Ying-Ming","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"173_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"key":"173_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221\u2013244.e3.","journal-title":"Gastroenterology"},{"key":"173_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.27609","volume":"61","author":"AM Di Bisceglie","year":"2015","unstructured":"Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle J. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703\u201311.","journal-title":"Hepatology"},{"key":"173_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14740338.2019.1577817","volume":"18","author":"G Murdaca","year":"2019","unstructured":"Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, et al. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opin Drug Saf. 2019;18:219\u201329.","journal-title":"Expert Opin Drug Saf"},{"key":"173_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297\u2013309.","journal-title":"Gastroenterology"},{"issue":"5 Suppl","key":"173_CR6","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl):S156\u201365.","journal-title":"Hepatology"},{"key":"173_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"173_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.rdc.2016.09.012","volume":"43","author":"C Koutsianas","year":"2017","unstructured":"Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin N Am. 2017;43:133\u201349.","journal-title":"Rheum Dis Clin N Am"},{"key":"173_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/MEG.0000000000001130","volume":"30","author":"YC Su","year":"2018","unstructured":"Su YC, Lin PC, Yu HC, Wu CC. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Eur J Gastroenterol Hepatol. 2018;30:925\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"173_CR10","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","volume":"10","author":"MH Kuo","year":"2020","unstructured":"Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate risk of hepatitis B virus reactivation in HBsAg\u2212\/HBcAb+ carriers receiving rituximab for rheumatoid arthritis. Sci Rep. 2020;10:2456.","journal-title":"Sci Rep"},{"key":"173_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13075-018-1748-z","volume":"20","author":"YC Tien","year":"2018","unstructured":"Tien YC, Yen HH, Li CF, Liu MP, Hsue YT, Hung MH, et al. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Res Ther. 2018;20:246.","journal-title":"Arthritis Res Ther"},{"key":"173_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","volume":"76","author":"W Fukuda","year":"2017","unstructured":"Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76:1051\u20136.","journal-title":"Ann Rheum Dis"},{"key":"173_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hep.29082","volume":"66","author":"S Paul","year":"2017","unstructured":"Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology. 2017;66:379\u201388.","journal-title":"Hepatology"},{"key":"173_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00277-012-1405-6","volume":"91","author":"SN Pei","year":"2012","unstructured":"Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91:1007\u201312.","journal-title":"Ann Hematol"},{"key":"173_CR15","first-page":"1","volume":"26","author":"YH Chen","year":"2012","unstructured":"Chen YH, Chien RN, Huang YH, Chen DY, Lan JL, Lu LY, et al. Screening and management of hepatitis B infection in rheumatic patients scheduled for biologic therapy: consensus recommendations from the Taiwan Rheumatology Association. Formos J Rheumatol. 2012;26:1\u20137.","journal-title":"Formos J Rheumatol"},{"key":"173_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s005350300025","volume":"38","author":"CH Hung","year":"2003","unstructured":"Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol. 2003;38:153\u20137.","journal-title":"J Gastroenterol"},{"key":"173_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12874-020-01007-w","volume":"20","author":"C Partlett","year":"2020","unstructured":"Partlett C, Hall NJ, Leaf A, Juszczak E, Linsell L. Application of the matched nested case-control design to the secondary analysis of trial data. BMC Med Res Methodol. 2020;20:117.","journal-title":"BMC Med Res Methodol"},{"key":"173_CR18","first-page":"111","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ. Case-control studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia: Williams & Wilkins; 2008. p. 111\u201327.","edition":"3"},{"key":"173_CR19","first-page":"811","volume-title":"Pharmacoepidemiology","author":"S Suissa","year":"2005","unstructured":"Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B, editor. Pharmacoepidemiology. 4th ed. New York: Wiley; 2005. p. 811\u201329.","edition":"4"},{"key":"173_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/ard.2010.144741","volume":"70","author":"WG Dixon","year":"2011","unstructured":"Dixon WG, Kezouh A, Bernatsky, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70:956\u201360.","journal-title":"Ann Rheum Dis"},{"key":"173_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000168436","volume":"12","author":"M Buti","year":"1992","unstructured":"Buti M, Viladomiu L, Jardi R, Olmos A, Rodriguez JA, Bartolome J, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992;12:144\u20137.","journal-title":"Am J Nephrol"},{"key":"173_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5414\/CNP68228","volume":"68","author":"I Tsouchnikas","year":"2007","unstructured":"Tsouchnikas I, Dounousi E, Xanthopoulou, Papakonstantinou S, Thomoglou V, Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol. 2007;68:228\u201334.","journal-title":"Clin Nephrol"},{"key":"173_CR23","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ndt\/15.8.1217","volume":"5","author":"U Sester","year":"2000","unstructured":"Sester U, Sester M, Hauk M, Kaul H, K\u00f6hler H, Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant. 2000;5:1217\u201323.","journal-title":"Nephrol Dial Transplant"},{"key":"173_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0891-5520(05)70174-4","volume":"15","author":"EL Pesanti","year":"2001","unstructured":"Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin N Am. 2001;15:813\u201332.","journal-title":"Infect Dis Clin N Am"},{"key":"173_CR25","first-page":"183","volume":"16","author":"B Descamps-Latscha","year":"1996","unstructured":"Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol. 1996;16:183\u201391.","journal-title":"Semin Nephrol"},{"key":"173_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4161\/hv.19107","volume":"8","author":"S Leonardi","year":"2012","unstructured":"Leonardi S, Vitaliti G, Garozzo MT, Miraglia del Giudice M, Marseglia G, La Rosa M. Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. Hum Vaccin Immunother. 2012;8:448\u201352.","journal-title":"Hum Vaccin Immunother"},{"key":"173_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jvh.12556","volume":"23","author":"EJ Joo","year":"2016","unstructured":"Joo EJ, Yeom JS, Kwon MJ, Chang Y, Ryu S. Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults. J Viral Hepat. 2016;23:889\u201396.","journal-title":"J Viral Hepat"},{"key":"173_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/v11090778","volume":"11","author":"I Lazarevic","year":"2019","unstructured":"Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-escape hepatitis B virus mutations associated with viral reactivation upon immunosuppression. Viruses. 2019;11:778.","journal-title":"Viruses"},{"key":"173_CR29","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1182\/blood-2003-05-1403","volume":"102","author":"TH Westhoff","year":"2003","unstructured":"Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930.","journal-title":"Blood"},{"key":"173_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","volume":"46","author":"A Tamori","year":"2011","unstructured":"Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556\u201364.","journal-title":"J Gastroenterol"},{"key":"173_CR31","first-page":"102","volume":"36","author":"I Papalopoulos","year":"2018","unstructured":"Papalopoulos I, Fanouriakis A, Kougas N, Flouri I, Sourvinos G, Bertsias G, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol. 2018;36:102\u20139.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-021-00173-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T09:15:53Z","timestamp":1617873353000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-021-00173-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["173"],"URL":"https:\/\/doi.org\/10.1186\/s42358-021-00173-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/661850","asserted-by":"object"}]},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical standards established by the 1964 Declaration of Helsinki and its later amendments. All participants provided written informed consent before any study-related procedure ensued.Changhua Christian Hospital Institutional Review Board approved the study protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}